EyeGate opens up U.S. operations

France's EyeGate Pharma has opened U.S. operations in Waltham, MA. EyeGate will focus on "iontophoretic technology to safely and non-invasively deliver therapeutics to the anterior and posterior chambers of the eye." President and CEO Stephen From will head up the company. From is a former venture capitalist and the CFO of Centelion SAS before it was bought out.

"My first hire at the company was Perry Calias, Ph.D., as VP, research and development," said From. "He was formerly senior director, drug delivery and chemistry at Eyetech Pharmaceuticals in Lexington, MA (now OSI), where he built a world-class lab to support the development of the marketed product, Macugen for age-related macular degeneration. With Dr. Calias' help, we have recruited a top-notch, veteran R&D team with unique ocular expertise, so the group has hit the ground running."

- see the press release for more information

Suggested Articles

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.